Evidence map›Paper›PMID 41783645›Full record

ArticleInternational journal of pharmaceutics: X2026

GPC3 and CD133-targeted peptide dual modification enhances the therapeutic effect of doxorubicin carried by OMVs on hepatocellular carcinoma.

Zuo Mou, Yuefeng Zhang, Xiaodian He, Mingze Zhang, Xiaoqin He, Wei Wang, Zehao Liu, Xinxin Xiong, Peng Ma, Kaihuan Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zuo MouDepartment of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Yuefeng ZhangDepartment of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Xiaodian HeThe First Clinical College, Wuhan University, Wuhan, China.
Mingze ZhangThe First Clinical College, Wuhan University, Wuhan, China.
Xiaoqin HeGeneral Administration Office, Renmin Hospital of Wuhan University, Wuhan, China.
Wei WangDepartment of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Zehao LiuDepartment of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Xinxin XiongSchool of Life Sciences, Northeast Normal University, Jilin, China.
Peng MaDepartment of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Kaihuan YuDepartment of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) has a high mortality rate because of the limitations of conventional chemotherapies (e.g., doxorubicin, DOX), including poor tumor targeting, systemic toxicity, and chemoresistance. Bacterial outer membrane vesicles (OMVs) are promising drug carriers but have limitations like nonspecific phagocytosis and weak targeting. In this study, a dual-targeted nanosystem ((GPC3 + CD133)

Indexed as

Drug deliveryHepatocellular carcinomaOuter membrane vesicleSparstolonin B

Identifiers

PMID41783645
PMCPMC12955658

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.